[98] A. Spenger, W. Ernst, J. P. Condreay, T. A. Kost, and R. Grabherr, “Influence of

promoter choice and trichostatin a treatment on expression of baculovirus delivered

genes in mammalian cells,” Protein Expr. Purif., vol. 38, pp. 17–23, 2004, doi: 10.

1016/j.pep.2004.08.001

[99] M. Fussenegger, J. E. Bailey, H. Hauser, and P. P. Mueller, “Genetic optimization

of recombinant glycoprotein production by mammalian cells,” Trends Biotechnol.,

vol. 17. pp. 35–42, 1999, doi: 10.1016/S0167-7799(98)01248-7

[100] E. Suzuki and D. F. Ollis, “Enhanced antibody production at slowed growth rates:

experimental demonstration and a simple structured model,” Biotechnol. Prog.,

vol. 6, no. 3, pp. 231–236, Jan. 1990, doi: 10.1021/bp00003a013

[101] C. A. Hall-Jackson, D. A. Cross, N. Morrice, and C. Smythe, “ATR is a caffeine-

sensitive, DNA-activated protein kinase with a substrate specificity distinct from

DNA-PK,” Oncogene, vol. 18, no. 48, pp. 6707–6713, Nov. 1999, doi: 10.1038/

sj.onc.1203077

[102] J. N. Sarkaria et al., “Inhibition of ATM and ATR kinase activities by the radio-

sensitizing agent, caffeine,” Cancer Res., vol. 59, no. 17, pp. 4375–4382, Sep. 1999,

Accessed: Feb. 11, 2015. [Online]. Available: http://www.ncbi.nlm.nih.gov/

pubmed/10485486

[103] W. D. Block, D. Merkle, K. Meek, and S. P. Lees-Miller, “Selective inhibition of

the DNA-dependent protein kinase (DNA-PK) by the radiosensitizing agent caf-

feine,” Nucleic Acids Res., vol. 32, no. 6, pp. 1967–1972, Jan. 2004, doi: 10.1093/

nar/gkh508

[104] B. L. Ellis, P. R. Potts, and M. H. Porteus, “Creating higher titer lentivirus with

caffeine,” Hum. Gene Ther., vol. 22, no. 1, pp. 93–100, Jan. 2011, doi: 10.1089/

hum.2010.068

[105] L. Cervera, J. Fuenmayor, I. González-Domínguez, S. Gutiérrez-Granados, M. M.

Segura, and F. Gòdia, “Selection and optimization of transfection enhancer ad-

ditives for increased virus-like particle production in HEK293 suspension cell

cultures,” Appl. Microbiol. Biotechnol., vol. 99, no. 23, pp. 9935–9949, 2015, doi:

10.1007/s00253-015-6842-4

[106] L. Cervera, S. Gutiérrez-Granados, N. S. Berrow, M. M. Segura, and F. Gòdia,

“Extended gene expression by medium exchange and repeated transient transfection

for recombinant protein production enhancement,” Biotechnol. Bioeng., vol. 112,

no. 5, pp. 934–946, 2015, doi: 10.1002/bit.25503

[107] J. Lavado-García, L. Cervera, and F. Gòdia, “An alternative perfusion approach for

the intensification of virus-like particle Production in HEK293 Cultures,” Front.

Bioeng. Biotechnol., vol. 8, Article number 617, 2020, doi: 10.3389/fbioe.2020.00617

[108] J. Lavado-García, I. Jorge, L. Cervera, J. Vázquez, and F. Gòdia, “Multiplexed

quantitative proteomic analysis of HEK293 provides insights into molecular

changes associated with the cell density effect, transient transfection, and virus-like

particle production,” J. Proteome Res., vol. 19, no. 3, pp. 1085–1099, Mar. 2020,

doi: 10.1021/acs.jproteome.9b00601

[109] D. J. Karst, E. Serra, T. K. Villiger, M. Soos, and M. Morbidelli, “Characterization

and comparison of ATF and TFF in stirred bioreactors for continuous mammalian

cell culture processes,” Biochem. Eng. J., vol. 110, pp. 17–26, 2016, doi: 10.1016/

j.bej.2016.02.003

[110] J. Lavado‐García, I. Jorge, A. Boix‐Besora, J. Vázquez, F. Gòdia, and L. Cervera,

“Characterization of HIV‐1 virus‐like particles and determination of Gag stoi-

chiometry for different production platforms,” Biotechnol. Bioeng., vol. 118,

pp. 2660–2675, Apr. 2021, doi: 10.1002/bit.27786

266

Bioprocessing of Viral Vaccines